Sagespring Wealth Partners LLC Takes Position in Amedisys, Inc. (NASDAQ:AMED)

Sagespring Wealth Partners LLC purchased a new stake in shares of Amedisys, Inc. (NASDAQ:AMED) during the 4th quarter, Holdings Channel reports. The fund purchased 2,883 shares of the health services provider’s stock, valued at approximately $262,000.

A number of other institutional investors also recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Amedisys in the fourth quarter valued at $83,061,000. Wealthfront Advisers LLC purchased a new stake in Amedisys in the 4th quarter worth about $72,970,000. Pacer Advisors Inc. raised its position in Amedisys by 11,621.9% in the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after purchasing an additional 553,435 shares during the period. Birnam Oak Advisors LP bought a new stake in Amedisys in the fourth quarter worth about $15,832,000. Finally, Calamos Advisors LLC boosted its position in shares of Amedisys by 22.7% during the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after buying an additional 90,097 shares during the period. 94.36% of the stock is currently owned by institutional investors.

Amedisys Stock Up 0.4 %

Shares of NASDAQ AMED opened at $91.91 on Thursday. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 36.47, a PEG ratio of 1.78 and a beta of 0.89. The stock has a 50 day moving average price of $92.16 and a 200 day moving average price of $91.98. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday. Stephens reiterated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.